glp-1 insurance coverage news in Employer Plans Could Nearly Double in 2024 MCT2D | 2023 Updates to
Description
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
doi: 10.1023/a:1018863716749
Tier 2: Cardiovascular Disease and Sleep Apnea Covered in Most States (Required Since 2024) Two newer FDA approvals expanded mandatory Medicaid coverage: Wegovy for cardiovascular risk reduction FDA-approved in March 2024 to reduce the risk of heart attack, stroke, and cardiovascular death in overweight or obese adults with established cardiovascular disease
Nigeria 19.3.9.4
The strongest risk factor for CVD and mortality in T2D is diabetic kidney disease (DKD) and DKD has been proposed to account for the majority of CVD risk observed in people with diabetes
Semaglutidea medication originally designed for type 2 diabetes that is now making headlines for its remarkable effectiveness in weight loss
